Shire has agreed to pay Sangamo BioSciences US$13 M upfront for the global rights to use the company’s zinc finger DNA-binding protein (ZFP) technology platform to develop therapies for haemophilia and other monogenic diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: PharmaDeals Ltd